In patients with local prostate cancer and high risk features (extension to surgical margins, seminal vesicles or prostate capsule), adjuvant radiotherapy after prostatectomy appears to improve overall survival and reduce the rate of distant metastases, but these effects are only evident with longer follow up.
The quality of evidence is downgraded by study limitations (selective outcome reporting).
A Cochrane review 1 included 3 studies with a total of 1815 patients, assessing the effect of adjuvant radiotherapy (RT) following radical prostatectomy (RP) in prostate cancer. Patients were at increased risk of relapse due to extension of disease to seminal vesicles, prostate capsule or surgical margins.
Adjuvant RT following RP did not affect overall survival (OS) at 5 years (RD (risk difference) 0.00; 95% CI -0.03 to 0.03), but improved survival at 10 years (RD -0.11; 95% CI -0.20 to -0.02). Adjuvant RT did not reduce metastatic disease at 5 years (RD -0.00; 95% CI -0.04 to 0.03), but reduced it at 10 years (RD -0.11; 95% CI -0.20 to -0.01). It improved local control at 5 and 10 years (RD -0.10; 95% CI -0.13 to -0.06 and RD -0.14; 95% CI -0.21 to -0.07, respectively), and biochemical progression-free survival at 5 years and 10 years (RD -0.16; 95% CI -0.21 to -0.11 and RD -0.29; 95% CI -0.39 to -0.19, respectively).
1. Daly T, Hickey BE, Lehman M et al. Adjuvant radiotherapy following radical prostatectomy for prostate cancer. Cochrane Database Syst Rev 2011;(12):CD007234. [PMID:22161411]
Copyright © 2020 Duodecim Medical Publications Limited.
Adjuvant radiotherapy following radical prostatectomy for prostate cancer with high risk characteristics
is a sample topic from the Evidence-Based Medicine Guidelines
To view other topics, please sign in or purchase a subscription.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Complete Product Information.
"Adjuvant Radiotherapy Following Radical Prostatectomy for Prostate Cancer With High Risk Characteristics." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/457545/all/Adjuvant_radiotherapy_following_radical_prostatectomy_for_prostate_cancer_with_high_risk_characteristics.
Adjuvant radiotherapy following radical prostatectomy for prostate cancer with high risk characteristics. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/457545/all/Adjuvant_radiotherapy_following_radical_prostatectomy_for_prostate_cancer_with_high_risk_characteristics. Accessed October 22, 2020.
Adjuvant radiotherapy following radical prostatectomy for prostate cancer with high risk characteristics. (2019). In Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited. Retrieved October 22, 2020, from https://evidence.unboundmedicine.com/evidence/view/EBMG/457545/all/Adjuvant_radiotherapy_following_radical_prostatectomy_for_prostate_cancer_with_high_risk_characteristics
Adjuvant Radiotherapy Following Radical Prostatectomy for Prostate Cancer With High Risk Characteristics [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2020 October 22]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/457545/all/Adjuvant_radiotherapy_following_radical_prostatectomy_for_prostate_cancer_with_high_risk_characteristics.
TY - ELEC
T1 - Adjuvant radiotherapy following radical prostatectomy for prostate cancer with high risk characteristics
ID - 457545
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/457545/all/Adjuvant_radiotherapy_following_radical_prostatectomy_for_prostate_cancer_with_high_risk_characteristics
PB - Duodecim Medical Publications Limited
DB - Evidence Central
DP - Unbound Medicine